VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2012

Sep 21, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2012-09-19

Reporting Person: Kelly Lisa (SVP, Human Resources)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-09-19	Common Stock	M	954	$32.16	Acquired	18203	Direct
2012-09-19	Common Stock	M	3093	$33.00	Acquired	21296	Direct
2012-09-19	Common Stock	S	4047	$57.61	Disposed	17249	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-09-19	Employee Stock Option (right to buy)	$32.16	M	954	Disposed	2018-07-23	Common Stock (954)	Direct
2012-09-19	Employee Stock Option (right to buy)	$33.00	M	3093	Disposed	2019-10-21	Common Stock (3093)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1957	Indirect

Footnotes

F1: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $57.61 (range $57.05 to $57.94).

F3: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Fully vested.